The glucagon-like peptide-1 receptor (GLP-1R) agonist exendin-4 (Ex-4) is a long-acting analog of the endogenous insulinotropic peptide, which has been approved as a treatment for type 2 diabetes mellitus [15]. Here, GLP1R is linked to diabetes mellitus.